Hemispherx Biopharma, Inc. (HEB)
Phone: (215) 988-0080
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen®.
NeoStem, Inc. (NBS)
NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the NeoStem with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
Advaxis, Inc. (ADXS)
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
ADXS-HPV is being evaluated in 5 clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), CIN 2/3 (US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.
Amarantus Biosciences, Inc. (AMBS)
Phone: (408) 737-2734
Amarantus BioScience, Inc. (“Amarantus”) is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death). The Company’s lead therapeutic program Mesencephalic-Astrocyte-derived Neurotrophic Factor, or MANF is a targeted therapeutic to address the underlying Programmed Cell Death (Apoptosis) associated with a wide range of devastating human disorders. The Company’s lead diagnostic program, NuroPro®, is aimed at developing diagnostic blood tests that are capable of early identification of apoptosis-related medical conditions while tracking their progression over time. Both programs will initially target Parkinson’s disease.
Galectin Therapeutics, Inc. (GALT)
Phone: (678) 620-3186
Galectin Therapeutics is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.